Download Image
    
Share
  
Post
c19early.org
Curcumin for COVID-19
28 studies with >15,000 patients
Serious outcome risk
Curcumin
Control
Significantly lower risk for mortality, ventilation, hospitalization, progression, recovery, and viral clearance.
44% lower risk in 21 RCTs CI 29-56%
Studies typically use advanced formulations for greatly improved bioavailability.
COVID-19 Curcumin studies · October 2026
Studies typically use advanced formulations for greatly improved bioavailability. Recent:
Suresh
Khan
Jena
Ataya.
Covid Analysis Curcumin reduces COVID-19 risk: real-time meta-analysis of 28 studies (Version 44)
Significantly lower risk is seen for mortality, ventilation, hospitalization, progression, recovery, and viral clearance. 19 studies from 17 independent teams in 9 countries show significant benefit. Meta-analysis using the most serious o..
Jul 31
 Khan et al., Pharmaceuticals, doi:10.3390/ph19081202 Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study
Single-arm study of 15 outpatients with mild-to-moderate long COVID showing reductions in symptom burden, fatigue, and pain with quercetin-curcumin treatment. There was no placebo or control group.
Mar 23
 Ataya et al., PLOS One, doi:10.1371/journal.pone.0345051 Identification of polyphenols as novel neuropilin-1 cendR pocket inhibitors to block SARS-CoV-2 entry and enhance variant resistance
In silico study showing that polyphenols, particularly 6"-O-acetyldaidzin and phloretin, bind to the neuropilin-1 (NRP-1) b1 domain CendR pocket with higher affinity than the synthetic inhibitor EG01377, potentially blocking SARS-CoV..
Jan 22
 Grüneberg et al., BMC Complementary Medicine and Therapies, doi:10.1186/s12906-026-05253-1 Dose-dependent antiviral effects of glycyrrhizin, curcumin, and harmaline against clinical SARS-CoV-2 isolates, including D614G, Omicron BA.5, and Omicron XBB.1
In vitro study in A549-AT cells showing that curcumin and glycyrrhizin effectively inhibit SARS-CoV-2 D614G, Omicron BA.5, and Omicron XBB.1 variants, while harmaline effectively inhibits only the Omicron variants, all at subtoxic concent..
Dec 17
2025
 Shokri-Afra et al., BioMed Research International, doi:10.1155/bmri/9507417 Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19
Review showing that SIRT1 activation may benefit COVID-19 treatment through multiple anti-inflammatory and antiviral mechanisms.
Dec 16
2025
 Jena et al., The Protein Journal, doi:10.1007/s10930-025-10309-1 Halved but Potent: Exploring the Inhibitory Property of Curcumin Derivatives Against Evolving SARS-CoV-2 Strains
In silico study showing that curcumin, half-curcumin, catechin, and 8-hydroxydihydrosanguinarine (8-HDS) bind strongly to the spike (S) proteins of SARS-CoV-2 D614G and B.1.1.7 variants, potentially inhibiting viral entry via ACE2.
Dec 3
2025
 Marzouk et al., BIO Web of Conferences, doi:10.1051/bioconf/202519804002 Computational and Experimental Insights into the Antiviral Mechanism of Turmeric (Curcuma longa) against SARS-CoV-2 D614G
In silico and in vitro study showing that turmeric (Curcuma longa) extract inhibits SARS-CoV-2 D614G virus-like particle entry in Vero E6 cells. Authors identified 24 bioactive compounds from turmeric extract using LC-HRMS analysis, with..
Oct 31
2025
 Sawangjit et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2025.103295 Effectiveness and Safety of Turmeric for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
61% lower mortality (p=0.0006), 65% lower ventilation (p=0.004), 64% lower progression (p<0.0001), and 26% improved recovery (p=0.0001). Systematic review and meta-analysis of 23 RCTs showing significantly lower mortality, ventilation, and progression, and improved recovery with turmeric treatment. Nano-curcumin was most commonly used for improved bioavailability and showe..
Sep 16
2025
 Shang et al., Journal of Integrative and Complementary Medicine, doi:10.1177/27683605251379004 Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
53% lower mortality (p=0.02). Systematic review and meta-analysis of six RCTs showing significantly lower COVID-19 mortality with nanocurcumin treatment.
Aug 21
2025
 Saleh et al., Scientific Reports, doi:10.1038/s41598-025-16092-4 A Triple-blind randomized controlled trial on the effects of turmeric versus ginger on inflammatory biomarkers in patients with COVID-19
RCT 144 COVID-19 outpatients showing a significant reduction in inflammatory markers (CRP and ESR) with both turmeric and ginger compared with placebo. There was no significant difference between groups for LDH or WBC. Baseline age differ..
Jul 16
2025
 Aktay et al., Phytotherapy Research, doi:10.1002/ptr.70046 Oral Administration of Water-Soluble Curcumin Complex Prevents ARDS With the Potential for COVID-19 Treatment
Mouse and in vitro study showing that orally administered water-soluble cyclodextrin-curcumin complex (CDC) protected C57BL/6 mice from Klebsiella or LPS-induced acute lung injury and down-regulated COVID-19 relevant pathways: treated ani..
Jun 4
2025
 Alcântara et al., Authorea Inc., doi:10.22541/au.174904567.74543434/v1 Earlier clinical improvement in mild-moderate acute COVID patients treated with pharmacological-grade Curcumin
37% improved recovery (p<0.0001). Prospective study of 131 mild-moderate COVID-19 patients showing significant reduction in time to symptom relief and complete recovery with pharmaceutical-grade curcumin.
Jun 2
2025
 Wu et al., Phytochemistry Letters, doi:10.1016/j.phytol.2025.102999 Utilizing natural compounds as ligands to disrupt the binding of SARS-CoV-2 receptor-binding domain to angiotensin-converting enzyme 2, impeding viral infection
In silico study showing that curcumin and arachidonic acid bind strongly to the SARS-CoV-2 receptor-binding domain (RBD), ACE2 receptor, and their complex interface, potentially disrupting viral infection. Curcumin demonstrated the highes..
May 26
2025
 Alici, H., Pharmaceuticals, doi:10.3390/ph18060798 Structure-Based Design and In-Silico Evaluation of Computationally Proposed Curcumin Derivatives as Potential Inhibitors of the Coronaviral PLpro Enzymes
In silico study showing that novel curcumin derivatives strongly bind to papain-like protease (PLpro) enzymes from SARS-CoV, MERS-CoV, and SARS-CoV-2 with superior binding affinities compared to natural curcumin and reference antivirals.
May 3
2025
 Kroon et al., iScience, doi:10.1016/j.isci.2025.112575 A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability
Crossover study of 9 healthy males comparing curcumin bioavailability from three commercial formulations (AOV, Longvida, NovaSOL). None of the three products tested contained the claimed amount of curcumin. Results showed plasma levels of..
Apr 30
2025
 Baqer et al., Medical Forum Monthly, doi:10.60110/medforum.360407 Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients
Open-label RCT 58 COVID-19 patients in Iraq reporting lower D-dimer with curcumin. No clinical endpoints (mortality, ICU admission, mechanical ventilation, length of stay) were reported, despite the abstract’s claim of mortality reduction..
Apr 28
2025
 Najimi et al., ChemistrySelect, doi:10.1002/slct.202406035 Phytochemical Inhibitors of SARS‐CoV‐2 Entry: Targeting the ACE2‐RBD Interaction with l‐Tartaric Acid, l‐Ascorbic Acid, and Curcuma longa Extract
In vitro and in silico study showing that l-tartaric acid, l-ascorbic acid, and Curcuma longa extract (curcumin, demethoxycurcumin, bisdemethoxycurcumin) inhibit the SARS-CoV-2 spike RBD interaction with human ACE2. Authors demonstrate by..
Apr 16
2025
 Morello et al., Italian Journal of Pediatrics, doi:10.1186/s13052-025-01961-5 Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review
Retrospective 1,243 children with COVID-19 showing lower risk of long COVID at 6 months when treated with a Multi-Element Product (MEP) containing antioxidants and anti-inflammatory compounds (magnesium 200 mg, quercetin 150 mg, curcumin ..
Apr 4
2025
 Olubiyi et al., Food Chemistry Advances, doi:10.1016/j.focha.2025.100969 Novel dietary herbal preparations with inhibitory activities against multiple SARS-CoV-2 targets: A multidisciplinary investigation into antiviral activities
In vitro and in silico study showing potent inhibition of SARS-CoV-2 main protease (3CLpro) by novel polyherbal dietary preparations. Curcumin was used as a positive control and inhibited protease activity by >95% at 50 μM.
Feb 20
2025
 Rajamanickam et al., Journal of Pharmacy and Pharmacology Research, doi:10.26502/fjppr.0105 Exploring the Potential of Siddha Formulation MilagaiKudineer-Derived Phytotherapeutics Against SARS-CoV-2: An In-Silico Investigation for Antiviral Intervention
In silico computational docking study of phytochemicals from MilagaiKudineer, showing potential inhibitory activity against SARS-CoV-2 targets. Authors evaluated binding affinities for the spike glycoprotein receptor-binding domain, RNA-d..
Jan 16
2025
 Sanduzzi Zamparelli et al., Life, doi:10.3390/life15010113 Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective
Review of immune-boosting and antiviral effects of antioxidants in COVID-19 pneumonia. Authors provide an overview of the literature on the use of antioxidants, including vitamins, trace elements, ozone, glutathione, L-carnitine, melatoni..
Dec 31
2024
 Duan et al., Trends in Food Science & Technology, doi:10.1016/j.tifs.2024.104864 Bioactive compounds,quercetin, curcumin and β-glucan,regulate innate immunity via the gut-liver-brain axis
Review of how bioactive compounds quercetin, curcumin, and β-glucan regulate innate immunity through the gut-liver-brain axis, with focus on COVID-19. Authors describe how SARS-CoV-2 infection triggers excessive immune activation and cyto..
Nov 27
2024
 Al balawi et al., Bioresources and Bioprocessing, doi:10.1186/s40643-024-00822-z Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study
In vitro and in silico study showing that propolis, curcumin, quercetin, and ginseng compounds inhibit SARS-CoV-2 infection and bind to key viral proteins. In Vero CCL-81 cells, propolis and curcumin significantly reduced SARS-CoV-2 viral..
Nov 21
2024
 Haque et al., Discover Molecules, doi:10.1007/s44345-024-00005-5 Exploring potential therapeutic candidates against COVID-19: a molecular docking study
In silico study showing potential inhibition of SARS-CoV-2 proteins by various compounds including dactinomycin, itraconazole, ivermectin, vitamin D, quercetin, curcumin, montelukast, bromhexine, hesperidin, EGCG and raloxifene. Authors p..
Sep 16
2024
 Emam et al., AMB Express, doi:10.1186/s13568-024-01739-8 Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors
In vitro study showing that curcumin, quercetin, gallic acid, and silymarin inhibit SARS-CoV-2 spike protein binding to the ACE2 receptor. Authors developed a novel immunofluorescent assay to screen potential inhibitors of the spike-ACE2 ..
Aug 11
2024
 Van Tin et al., Cells, doi:10.3390/cells13161331 Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling
In vitro study showing that the SARS-CoV-2 spike protein can activate cardiac fibroblasts through ACE2-dependent mechanisms, leading to cardiac fibrosis via the NLRP3 inflammasome and NF-κB signaling pathways. The results suggest that COV..
Jul 1
2024
 Li et al., Animals and Zoonoses, doi:10.1016/j.azn.2024.06.001 Thermal shift assay (TSA)-based drug screening strategy for rapid discovery of inhibitors against the Nsp13 helicase of SARS-CoV-2
In vitro study showing that 11 compounds inhibited the SARS-CoV-2 helicase Nsp13, with 7 compounds inhibiting ATPase activity and 4 inhibiting RNA unwinding activity at micromolar concentrations. Authors screened 1,970 FDA-approved drugs ..
Jun 24
2024
 Kishimoto et al., Journal of Health, Population and Nutrition, doi:10.1186/s41043-024-00584-6 Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial
47% lower progression (p=0.48). RCT 138 COVID-19 outpatients in Japan showing lower progression to fever and hypoxemia with curcuRouge, a highly bioavailable oral curcumin formulation, compared to placebo. The curcuRouge group also had a greater reduction in body temper..
Jun 3
2024
 Kamble et al., Emergent Materials, doi:10.1007/s42247-024-00754-6 Nanoparticulate curcumin spray imparts prophylactic and therapeutic properties against SARS-CoV-2
In vitro study showing that a water-dispersible nano-spray formulation of curcumin inhibits SARS-CoV-2 infection in Vero E6 cells. Authors found that pre-treatment effectively inhibited SARS-CoV-2 infection, and subsequent exposure to the..
May 31
2024
 Zhang et al., Phytomedicine, doi:10.1016/j.phymed.2024.155784 Computational Discovery of Mitochondrial Dysfunction Biomarkers in Severe SARS-CoV-2 Infection: Facilitating Pytomedicine Screening
In silico and in vitro study showing potential benefits of curcumin for severe COVID-19 by protecting mitochondrial function and reducing dysregulated metabolism and immune response. Authors identified five mitochondrial dysfunction bioma..
May 31
2024
 Rajak et al., Biotechnology of Medicinal Plants with Antiallergy Properties, doi:10.1007/978-981-97-1467-4_4 Antiallergic Implications of Curcumin During COVID-19: Current Status and Perspectives
Review of the potential of curcumin for allergic and inflammatory reactions in COVID-19. Authors highlight that curcumin has numerous health benefits, including antioxidative, anti-inflammatory, antidiabetic, and antimicrobial activities...
May 30
2024
 Öztürkkan et al., Baku State University Journal of Chemistry and Material Sciences, 1:2 In Silico investigation of the effects of curcuminoids on the spike protein of the omicron variant of SARS-CoV-2
In silico study showing potential inhibition of SARS-CoV-2 omicron variant spike protein by curcuminoids. Authors performed molecular docking studies to examine interactions between curcumin, demethoxycurcumin, and bis-demethoxycurcumin w..
May 29
2024
 Yunze et al., Research Square, doi:10.21203/rs.3.rs-4329762/v1 Therapeutic effect and potential mechanism of curcumin, an active ingredient in Tongnao Decoction, on COVID-19 combined with stroke: a network pharmacology study and GEO database mining
In silico study showing that curcumin, the active ingredient in Tongnao Decoction, may be beneficial for COVID-19 combined with stroke through the CCNA2, JAK2, MMP9, PPARG, PTGS2, and STAT3 target pathways, with MMP9 being the most import..
May 10
2024
 Nicoliche et al., Scientific Reports, doi:10.1038/s41598-024-61662-7 Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2
In vitro study showing antiviral, anti-inflammatory, and antioxidant effects of curcumin and curcuminoids in SARS-CoV-2 infected SH-SY5Y human neuroblastoma cells. Authors found that the curcuminoid Me23 significantly decreased expression..
May 4
2024
 Kali et al., Global Journal of Medical, Pharmaceutical, and Biomedical Update, doi:10.25259/GJMPBU_78_2023 Curcumin as a Promising Therapy for COVID-19: A Review
Review of curcumin for COVID-19. Authors discuss the molecular mechanisms of COVID-19 pathogenesis and the properties and mechanisms of action of curcumin. Curcumin exhibits antiviral activity against SARS-CoV-2 by interfering with viral ..
Apr 16
2024
 Agamah et al., ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1 Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases
In silico study identifying potential drugs beneficial for COVID-19 by integrating transcriptomics, proteomics, metabolomics, lipidomics, and drug data. Authors explore interactions between drugs, molecular features, and disease severity...
Apr 13
2024
 Vaiss et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2024.106766 Curcumin and quercetin co-encapsulated in nanoemulsions for nasal administration: a promising therapeutic and prophylactic treatment for viral respiratory infections
In vitro and ex vivo study showing that curcumin and quercetin co-encapsulated in nanoemulsions (NEs) for nasal administration inhibited murine β-coronavirus (MHV-3) infection. MHV-3 belongs to the same family as SARS-CoV-2. Authors found..
Apr 7
2024
 Boseila et al., European Journal of Pharmaceutics and Biopharmaceutics, doi:10.1016/j.ejpb.2024.114279 Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2
In silico, in vitro, and rat study showing potential prophylactic and therapeutic benefits of a curcumin-loaded self-nanoemulsifying drug delivery system throat spray against SARS-CoV-2 infection and pharyngitis. Molecular docking studies..
Mar 18
2024
 Vajdi et al., Pharmacological Reports, doi:10.1007/s43440-024-00585-6 Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy
Review of polyphenols for COVID-19. Authors note that polyphenols can inhibit key SARS-CoV-2 enzymes involved in viral replication and infection, and that many polyphenols have well-established safety profiles. Authors recommend additiona..
Feb 29
2024
 Yong et al., International Journal of Nanomedicine, doi:10.2147/ijn.s451206 Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases
Review of nanoformulations for inhaled therapeutics for respiratory diseases including potential for COVID-19. Inhaled formulations deliver treatment directly to both the upper and lower respiratory tract, enabling higher local concentrat..
Feb 6
2024
 Hidayah et al., International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724 Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition
In silico study showing binding of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin to the SARS-CoV-2 nucleocapsid protein. Authors find curcumin has the strongest predicted binding affinity. All compounds showed suitab..
Jan 30
2024
 Halma et al., Endocrine and Metabolic Science, doi:10.1016/j.endmts.2024.100163 Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology
Review of autophagy pathways for treating SARS-CoV-2 spike protein-related pathology. Authors note that the spike protein is implicated in long COVID and post-vaccination syndrome through mechanisms like inflammation, vascular damage, and..
Jan 29
2024
 Singh et al., Research Square, doi:10.21203/rs.3.rs-3888947/v1 Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach
In silico and in vitro study including quercetin and curcumin derivatives as potential SARS-CoV-2 main protease (Mpro) inhibitors. Molecular dynamics simulations and virtual screening identified quercetin and curcumin derivatives demethox..
Jan 23
2024
 Nittayananta et al., Virology Journal, doi:10.1186/s12985-023-02282-x A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity
In vitro study showing that a novel oro-nasal curcumin film spray inhibits SARS-CoV-2 and influenza virus infection of cells while enhancing mucosal innate immunity. The spray demonstrated potent dose-dependent antiviral activity against ..
Jan 9
2024
 Arab et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2024.116131 Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19
Review of immunoregulatory effects of nanocurcumin in inflammatory conditions including COVID-19. Authors note that curcumin has shown therapeutic potential but has poor bioavailability, which nanoformulations can address. Studies suggest..
Jan 4
2024
 Kant et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2023.2300060 Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors
In silico study showing that curcumin strongly inhibits the interaction between the SARS-CoV-2 spike protein receptor binding domain (RBD) and the human ACE2 receptor for the delta and omicron variants. Molecular docking and dynamics simu..
Dec 31
2023
 Teixeira et al., Curcumin and Neurodegenerative Diseases, doi:10.1007/978-981-99-7731-4_14 Effect of Curcumin on the Process of Neuroinflammation Caused by COVID-19
Review of the effect of curcumin on neuroinflammation caused by COVID-19. Authors note that curcumin has antioxidant, anti-inflammatory, antiviral, neuroprotective, and immune-modulating properties that may be helpful before and after SAR..
Dec 31
2023
 Daskou et al., Pathogens, doi:10.3390/pathogens13010039 The Role of the NRF2 Pathway in the Pathogenesis of Viral Respiratory Infections
Review discussing the role of the NRF2 antioxidant pathway in regulating viral replication and associated inflammation and cell damage pathways during respiratory viral infections. Authors summarize evidence showing that respiratory virus..
Dec 25
2023
 Law et al., Pharmaceuticals, doi:10.3390/ph17010034 Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review
Review of the use of curcumin and methylene blue as photosensitizers in photodynamic therapy (PDT) against bacteria and SARS-CoV-2. Authors explains the principles behind PDT and the mechanisms of curcumin and methylene blue as photosensi..
Dec 20
2023
 Lee et al., Functional Foods in Health and Disease, doi:10.31989/ffhd.v13i12.1207 Safety evaluation of high bioavailability curcumin in Healthy Japanese Adults: A Randomized, placebo-controlled, double-blind, parallel-group comparison study
Safety RCTs for highly bioavailable curcumin supplements CR-033P and TS-P1 in healthy Japanese adults, testing 150 mg/day curcumin equivalent of CR-033P or TS-P1 for 12 weeks, and 750 mg/day curcumin equivalent of TS-P1 for 4 weeks. Both ..
Dec 15
2023
 Donzelli, A., MDPI AG, doi:10.20944/preprints202312.1178.v1 Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review
Review of a group of compounds with efficacy shown in RCTs, safety, favorable opportunity costs, biological plausibility, and accessibility without major conflicts of interest. The compounds include curcumin, nigella sativa (black seed), ..
Nov 30
2023
 Naderi Beni et al., PLOS ONE, doi:10.1371/journal.pone.0295014 In silico studies of anti-oxidative and hot temperament-based phytochemicals as natural inhibitors of SARS-CoV-2 Mpro
In silico study showing potential benefits of the phytochemicals curcumin, savinin, and betulinic acid as an inhibitor of the SARS-CoV-2 main protease (Mpro). Molecular docking analysis revealed these hot temperament, antioxidant compound..
Nov 21
2023
 Hulscher et al., Cureus, doi:10.7759/cureus.49204 Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination
Review of evidence that the SARS-CoV-2 spike protein can damage cardiovascular, hematological, neurological, respiratory, gastrointestinal, and immunological systems, and may be a primary cause of long COVID symptoms. Authors introduce a ..
Nov 15
2023
 Bhardwaj et al., Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2023.100778 Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial
13% shorter hospitalization (p=0.05) and 12% faster viral clearance (p=0.02). RCT 150 mild-moderate COVID-19 patients showing faster viral clearance and shorter hospitalization with NAOQ19, a polyherbal formulation containing 13 antiviral/antinflammatory compounds. NAOQ19 ingredients include curcumin, andrographis,..
Nov 2
2023
 Moschovou et al., International Journal of Molecular Sciences, doi:10.3390/ijms242115894 Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein
In silico molecular docking and molecular dynamics analysis identifying curcumin, quercetin, rosmarinic acid, and salvianolic acid B as having favorable binding to Mpro and three distinct sites on the S protein. Molecular dynamics simulat..
Oct 16
2023
 Eleraky et al., International Journal of Nanomedicine, doi:10.2147/IJN.S423251 Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2
In silico, in vitro, and in vivo study showing antiviral efficacy of a curcumin nanoformulation against SARS-CoV-2. Molecular docking revealed potential binding and inhibition of curcumin with viral proteins involved in entry and replicat..
Sep 29
2023
 Septisetyani et al., bioRxiv, doi:10.1101/2023.09.28.560070 Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion
In vitro study showing that curcumin inhibits SARS-CoV-2 pseudovirus cell entry and syncytia formation at 1-10μM in cells overexpressing ACE2 and TMPRSS2. Authors find that both curcumin and turmeric extract are potential inhibitors of SA..
Sep 21
2023
 Singh et al., The Seybold Report, doi:10.17605/OSF.IO/TKEXJ Computational studies to analyze effect of curcumin inhibition on coronavirus D614G mutated spike protein
In silico study showing that curcumin binds strongly to both the SARS-CoV-2 spike protein and ACE2 receptor. Curcumin's binding energy was similar for the wildtype spike protein and a mutated D614G variant.
Sep 19
2023
 Thapa et al., Makara Journal of Science, doi:10.7454/mss.v27i3.1609 In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2
In silico analysis showing that curcumin and quercetin may be beneficial for COVID-19 by binding to the main protease (Mpro), spike protein, and ACE2 receptor. Both compounds had suitable ADME properties and minimal predicted toxicity.
Sep 16
2023
 Mohd Abd Razak et al., Natural Product Communications, doi:10.1177/1934578X231188861 In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds
In vitro study showing that of 9 phenolic compounds tested, only curcumin inhibited SARS-CoV-2 cytopathic effects in infected monkey kidney Vero E6 cells. Curcumin showed antiviral activity against wildtype, alpha, delta, and omicron vari..
Aug 30
2023
 Srivastava et al., Stresses, doi:10.3390/stresses3030043 Paradigm of Well-Orchestrated Pharmacokinetic Properties of Curcuminoids Relative to Conventional Drugs for the Inactivation of SARS-CoV-2 Receptors: An In Silico Approach
In silico analysis of curcuminoids showing similar drug-like properties and strong binding to the main protease and spike receptor binding domain proteins. Curcuminoid binding was comparable or better than existing drugs favipiravir, remd..
Aug 25
2023
 Alkafaas et al., Virology Journal, doi:10.1186/s12985-023-02160-6 A study on the effect of natural products against the transmission of B.1.1.529 Omicron
Review of natural products for SARS-CoV-2 omicron including an in silico study showing quercetin, curcumin, ascorbic acid, nigellidine, and chloroquine among many compounds docked to the ACE2 metallopeptidase domain. Quercetin, curcumin, ..
Aug 3
2023
 Micek et al., Frontiers in Nutrition, doi:10.3389/fnut.2023.1241016 Association of dietary intake of polyphenols, lignans, and phytosterols with immune-stimulating microbiota and COVID-19 risk in a group of Polish men and women
Dietary analysis of 95 adults in Poland, showing lower risk of COVID-19 with higher intake of polyphenols, lignans, and phytosterols. Results were statistically significant for total phytosterols, secoisolariciresinol, β-sitosterol, matai..
Jul 28
2023
 Ahmadi et al., International Journal of Clinical Practice, doi:10.1155/2023/5734675 Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial
58% lower need for oxygen therapy (p=0.06) and 67% improved recovery (p=0.04). RCT 76 hospitalized patients, showing improved recovery with nanocurcumin. Authors note that pure curcumin is limited due to rapid metabolism, low bio-availability, weak aqueous solubility, and systemic deletion, and that the nanocurcumin..
Jun 30
2023
 Winih Kinasih et al., Duta Pharma Journal, doi:10.47701/djp.v3i1.2904 Analisis in silico interaksi senyawa kurkuminoid terhadap enzim main protease 6LU7 dari SARS-CoV-2
In silico study of the interaction between curcumin and its derivatives with the main protease enzyme from SARS-CoV-2. The compounds tested were curcumin, bisdemethoxycurcumin, and demethoxycurcumin. All compounds met the requirements of ..
Jun 22
2023
 Gérain et al., Frontiers in Nutrition, doi:10.3389/fnut.2023.1137407 NASAFYTOL® supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial
91% lower combined mortality/ICU admission (p=0.02), 89% lower ventilation (p=0.05), 89% lower ICU admission (p=0.05), and 73% higher hospital discharge (p=0.07). RCT 49 hospitalized COVID-19 patients, 25 treated with curcumin and quercetin, shower lower mortality/ICU admission and improved recovery with treatment. All patients received vitamin D. 336mg curcumin, 520mg quercetin, and 18μg vitamin D..
Apr 29
2023
 Sadeghizadeh et al., Phytotherapy Research, doi:10.1002/ptr.7844 Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID‐19 patients: A randomized, double‐blinded, placebo‐controlled trial
92% lower progression (p=0.02), 25% shorter hospitalization (p=0.007), and 68% improved recovery (p<0.0001). RCT 42 hospitalized moderate/severe COVID-19 patients in Iran, showing lower progression and improved recovery with nano-curcumin. Nano-curcumin 70mg bid for 14 days.
Apr 13
2023
 Wu et al., Research Square, doi:10.21203/rs.3.rs-2780614/v1 Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2
In vitro study showing that curcumin and resveratrol inhibit SARS-CoV-2 infection through multiple mechanisms. Curcumin and resveratrol inhibit SARS-CoV-2 pseudovirus cell entry in HEK293-ACE2 cells with IC50 values of 18.02 μM and 8.76 μ..
Apr 13
2023
 Barh et al., Indian Journal of Medical Research, doi:10.4103/ijmr.ijmr_1701_22 Indian food habit & food ingredients may have a role in lowering the severity & high death rate from COVID-19 in Indians: findings from the first nutrigenomic analysis
Nutrigenomics study of blood transcriptomes from Indian and western COVID-19 patients, showing Indian dietary habits and food ingredients including higher zinc, iron, curcumin, fiber, catechins, and EGCG may be associated with reduced sev..
Apr 1
2023
 Fam et al., Scientific Reports, doi:10.1038/s41598-023-31764-9 Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites
In vitro study showing that adamantane derivatives and six out of ten tested polyphenols including curcumin and quercetin inhibited the SARS-CoV-2 viroporin ORF3a, which contributes to viral pathogenicity and cytotoxicity. Authors used ce..
Mar 28
2023
 Teshima et al., Natural Product Research, doi:10.1080/14786419.2023.2194647 Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells
In vitro study of curcumin and its analogs with 6 of 8 compounds showing SARS-CoV-2 antiviral activity with EC50 values <30μM and binding inhibitory activity with IC20 values <30μM.
Mar 13
2023
 Hegde et al., ACS Omega, doi:10.1021/acsomega.2c07326 Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Review of clinical studies on curcumin formulations for improved bioavailability. Authors note that bioavailability has been improved by a factor of >50,000.
Feb 21
2023
 Savaliya et al., AYU (An International Quarterly Journal of Research in Ayurveda), doi:10.4103/ayu.ayu_92_22 Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial
86% improved recovery (p<0.0001) and 53% improved viral clearance (p<0.0001). RCT with 300 mild to moderate hospitalized COVID-19 patients, showing faster recovery, faster viral clearance, and a reduction in inflammatory markers with COROPROTECT, which includes curcumin, andrographis, and several additional treatme..
Feb 17
2023
 Shojaei et al., Phytotherapy Research, doi:10.1002/ptr.7778 The effectiveness of nano‐curcumin on patients with COVID‐19: A systematic review of clinical trials
Meta analysis of 8 nano-curcumin COVID-19 studies, showing significantly lower mortality and shorter hospitalization with treatment.
Jan 18
2023
 Das et al., Archives of Clinical and Medical Case Reports, 7:1 The Efficacy of a Plant Based Formulation in the Symptomatic Management of Mild COVID-19 Cases: A Double Blind, Randomized Controlled Trial
98% improved recovery (p<0.0001) and 76% improved viral clearance (p<0.0001). RCT 50 patients in India testing NAOQ19 which includes curcumin along with many other ingredients, showing improved recovery and viral clearance. SOC included vitamin C and zinc. NAOQ19 is a plant based formulation with 19 ingredients fro..
Jan 18
2023
 Din Ujjan et al., Frontiers in Nutrition, doi:10.3389/fnut.2022.1023997 The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial
29% improved recovery (p=0.11) and 91% improved viral clearance (p=0.05). Small RCT with 50 outpatients, 25 treated with curcumin, quercetin, and vitamin D, showing improved recovery and viral clearance with treatment. 168mg curcumin, 260mg, 360IU vitamin D3 daily for 14 days. Unadjusted baseline differences: t..
Jan 14
2023
 Shafiee et al., Phytotherapy Research, doi:10.1002/ptr.7724 Curcumin for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials
62% lower mortality (p=0.003). Meta analysis of 13 curcumin RCTs showing lower mortality with treatment. Authors note that subgroup analysis suggested improved efficacy with early treatment and with combined treatment.
Jan 10
2023
 Suresh et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13744 Therapeutic potential of curcumin in ARDS and COVID‐19
Review of the therapeutic potential of curcumin, specifically cyclodextrin-complexed curcumin, for treating ARDS and COVID-19.
Nov 23
2022
 Chitre et al., Phytotherapy Research, doi:10.1002/ptr.7683 Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers
11% faster recovery (p=0.04). RCT 208 moderate COVID-19 patients in India, 103 treated with a combination of turmeric, ashwagandha, boswellia, and ginger, showing improved recovery with treatment. The dose of curcumin is unknown and bioavailability may be poor.
Sep 27
2022
 Zupin et al., Viruses, doi:10.3390/v14102132 Optimization of Anti-SARS-CoV-2 Treatments Based on Curcumin, Used Alone or Employed as a Photosensitizer
In vitro study showing that curcumin inhibits SARS-CoV-2 replication and can be used as a photosensitizer in photodynamic therapy. Authors found that 10 μM curcumin directly applied to the virus before cell inoculation inhibited SARS-CoV-..
Sep 17
2022
 Abbaspour-Aghdam et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2022.175267 Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function
71% lower mortality (p=0.15) and 86% improved recovery (p=0.04). RCT with 30 nanocurcumin and 30 control patients in Iran, showing lower mortality and improved recovery, without statistical significance, and improved NK cell function. 160mg nanocurcumin for 21 days.
Jun 30
2022
 Khan et al., Frontiers in Virology, doi:10.3389/fviro.2022.923018 Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry
In vitro study showing that dimethoxycurcumin (DiMC), a methylated analog of curcumin, blocked the entry of SARS-CoV-2 pseudovirus into human lung Calu-3 cells and monkey kidney Vero E6 cells at 2-4μM concentrations. DiMC acidified endoly..
Jun 10
2022
 Nimer et al., F1000Research, doi:10.12688/f1000research.121933.1 Effect of natural products use prior to infection with COVID-19 on disease severity and hospitalization: A self-reported cross-sectional survey study
31% lower hospitalization (p=0.08) and 13% lower severe cases (p=0.47). Survey 2,148 COVID-19 recovered patients in Jordan, showing lower hospitalization with turmeric prophylaxis, not reaching statistical significance.
Jun 6
2022
 Askari et al., Trials, doi:10.1186/s13063-022-06375-w The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial
26% improved recovery (p=0.26). Small RCT 46 outpatients in Iran, 23 treated with curcimin-piperine, showing no significant difference in recovery. 1000mg curcumin and 10mg piperine/day for 14 days.
May 19
2022
 Hellou et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337 Effect of ArtemiC in patients with COVID-19: A Phase II prospective study
77% improved recovery (p=0.04), 92% lower need for oxygen therapy (p=0.01), 13% shorter hospitalization (p=0.92), and 10% improved viral clearance (p=0.77). RCT 50 hospitalized patients in Israel, 33 treated with curcumin, vitamin C, artemisinin, and frankincense oral spray, showing improved recovery with treatment.
May 1
2022
 Nag et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552 Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
In silico study showing showing significant inhibitory potential of curcumin for omicron.
May 1
2022
 Khan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062 Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial
33% improved recovery (p=0.15) and 50% improved viral clearance (p=0.009). RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). 168mg curcumin, 260mg ..
Apr 28
2022
 Kow et al., Phytotherapy Research, doi:10.1002/ptr.7468 The effect of curcumin on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials
77% lower mortality (p=0.002). Meta analysis of 3 curcumin RCTs showing lower mortality with treatment. Author notes the small sample sizes of the included trials.
Apr 9
2022
 Leka et al., Phytotherapy Research, doi:10.1002/ptr.7463 In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds
In vitro study showing antiviral activity of curcumin longa, with protection against SARS-CoV-2-induced cytopathic effects at a concentration of 3.125μg/ml.
Mar 25
2022
 Sankhe et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824 A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
86% lower mortality (p=0.24), 86% lower ventilation (p=0.24), 10% shorter hospitalization (p=0.4), and 32% faster recovery (p=0.001). RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurco..
Mar 22
2022
 Thomas et al., COVID, doi:10.3390/covid2040031 A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study
44% greater improvement (p=0.02). RCT 147 long COVID patients in the UK, 56 treated with a phytochemical-rich concentrated food capsule, showing improved recovery with treatment. Treatment included curcumin, bioflavonoids, chamomile, ellagic acid, and resveratrol.
Feb 28
2022
 Shehab et al., Tropical Journal of Pharmaceutical Research, doi:10.4314/tjpr.v21i2.13 Immune-boosting effect of natural remedies and supplements on progress of, and recovery from COVID-19 infection
42% lower severe cases (p=0.55). Retrospective survey-based analysis of 349 COVID-19 patients, showing a lower risk of severe cases with vitamin D, zinc, turmeric, and honey prophylaxis in unadjusted analysis, without statistical significance. REC/UG/2020/03.
Feb 22
2022
 Hartono et al., Pharmacognosy Journal, doi:10.5530/pj.2022.14.27 The Effect of Curcumin and Virgin Coconut Oil Towards Cytokines Levels in COVID-19 Patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia
53% improved viral clearance (p<0.0001). RCT with 30 patients treated with curcumin and virgin coconut oil (VCO), and 30 SOC patients in Indonesia, showing faster viral clearance with treatment. Treatment also reduced IL-1β, IL-2, IL-6, IL-18, and IFN-β levels. VCO improves the..
Feb 4
2022
 Rampogu et al., International Journal of Molecular Sciences, doi:10.3390/ijms23031771 Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2
In silico molecular dynamics simulation study finding a curcumin analogue (curA) as a promising dual inhibitor for SARS-CoV-2.
Jan 28
2022
 Kartika et al., ICE on IMERI, 2021 Curcumin as adjuvant Therapy in Mild - Moderate Covid 19
41% shorter hospitalization (p=0.05). Retrospective 246 hospitalized patients in Indonesia, 136 treated with curcumin, showing shorter hospitalization time with treatment. All patients received vitamin C, D, and zinc.
Jan 21
2022
 Goc et al., European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022 Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants
In vitro study testing combinations of plant extracts and micronutrients with several variants of SARS-CoV-2. A combination of vitamin C, N-acetylcysteine, curcumin, quercetin, resveratrol, theaflavin, naringenin, baicalin, and broccoli e..
Jan 17
2022
 Asadirad et al., Phytotherapy Research, doi:10.1002/ptr.7375 Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial
26% lower mortality (p=0.74), 50% lower progression (p=0.47), and 45% improved recovery (p=0.09). RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.
Jan 12
2022
 Honarkar Shafie et al., Phytotherapy Research, doi:10.1002/ptr.7374 Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial
29% shorter hospitalization (p=0.22) and 9% improved recovery. RCT 48 hospitalized patients in Iran, 24 treated with nanocurcumin, showing lower hospitalization time with treatment. The number of patients shown in Table 3 (31 and 27 for each arm) is inconsistent with the number reported as randomized..
Jan 7
2022
 Vahedian-Azimi et al., Nutrients, doi:10.3390/nu14020256 Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials
Review of 6 COVID-19 curcumin studies showing that treatment resulted in significant improvement in symptoms, duration of hospitalization, and mortality, and a significant decrease in proinflammatory cytokines and increase in anti-inflamm..
Dec 27
2021
 Bhardwaja et al., Research Square, doi:10.21203/rs.3.rs-1165680/v1 An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial
89% improved recovery (p=0.05) and 24% improved viral clearance (p=0.47). Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin, andrographis, and antiandrogen glycyrrhiza glabra.
Nov 16
2021
 Marín-Palma et al., Molecules, doi:10.3390/molecules26226900 Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms
In vitro study showing antiviral and anti-inflammatory effects of curcumin during SARS-CoV-2 infection. Inhibition was seen with Vero E6 cells pre-infection and post-infection, and with D614G and the delta variant. The anti-inflammatory e..
Nov 14
2021
 Bahun et al., Food Chemistry, doi:10.1016/j.foodchem.2021.131594 Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols
In silico and in vitro study of plant polyphenols identifying quercetin, curcumin, ellagic acid, epigallocatechin gallate, and resveratrol as SARS-CoV-2 3CLpro inhibitors with IC50 between 11.8µM and 23.4µM. Real-time binding was analyzed..
Oct 22
2021
 Singh et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965 Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach
In silico study showing strong binding affinity of curcumin and diacetylcurcumin with SARS-CoV-2 RNA-dependent RNA polymerase. Comparison with remdesivir and favipiravir suggested greater potential of these compounds as an RdRp inhibitor.
Oct 11
2021
 Majeed et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients
43% improved recovery (p=0.004) and 6% faster viral clearance (p=0.47). RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.
Sep 23
2021
 Bormann et al., Viruses, doi:10.3390/v13101914 Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro
In vitro study showing curcumin neutralizes SARS-CoV2 in vitro with low subtoxic concentrations. Authors note that the clinical use of curcumin is hindered by poor bioavailability, and recommend using methods to increase bioavailability s..
Sep 19
2021
 Hassaniazad et al., Phytotherapy Research, doi:10.1002/ptr.7294 A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
46% worse recovery (p=0.9). Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune re..
Sep 8
2021
 Chabot et al., Cureus, doi:10.7759/cureus.17829 Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia
Small case study of 2 patients, showing significant improvement in taste and smell shortly after one dose of a turmeric supplement. Authors note that the risk of one dose is low in healthy individuals not on medications metabolized by cyt..
Aug 10
2021
 Sankhe et al., Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6 A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID
89% lower mortality (p=0.12), 75% lower ventilation (p=0.37), 46% improved recovery (p=0.002), and 10% shorter hospitalization (p=0.4). RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245.
Jul 9
2021
 Panda et al., Medicine, doi:10.1097/MD.0000000000026601 The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability.
Jun 29
2021
 Guijarro-Real et al., Foods, doi:10.3390/foods10071503 Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
In vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLpro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLpro activity, but did not fully account for the inhibitory effect of turmeric rh..
Jun 19
2021
 Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
86% lower hospitalization (p=0.24) and 21% faster recovery (p=0.37). RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
Jun 17
2021
 Goc et al., PLOS ONE, doi:10.1371/journal.pone.0253489 Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions
In vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen fo..
Jun 15
2021
 Kandeil et al., Pathogens, doi:10.3390/pathogens10060758 Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2
Vero E6 in vitro study showing curcumin, hesperidin, and quercetin significantly inhibited SARS-CoV-2 replication, and in silico analysis with promising Mpro and spike docking results.
May 28
2021
 Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
82% lower mortality (p=0.02). RCT 140 patients, 70 treated with curcumin and piperine (for absorption), and 70 treated with probiotics, showing faster recovery, lower progression, and lower mortality with curcumin.
May 11
2021
 Aldwihi et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18105086 Patients’ Behavior Regarding Dietary or Herbal Supplements before and during COVID-19 in Saudi Arabia
31% lower hospitalization (p=0.1). Retrospective survey-based analysis of 738 COVID-19 patients in Saudi Arabia, showing lower hospitalization with vitamin C, turmeric, zinc, and nigella sativa, and higher hospitalization with vitamin D. For vitamin D, most patients contin..
May 7
2021
 Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 Curcumin as a Potential Treatment for COVID-19
Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects.
Mar 28
2021
 Tahmasebi et al., Life Sciences, doi:10.1016/j.lfs.2021.119437 Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
83% lower mortality (p=0.11). RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin).
Feb 28
2021
 Bejan et al., Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2376 (date from preprint) DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing
59% lower hospitalization (p=0.05). Retrospective 9,748 COVID-19 patients in the USA showing lower hospitalization with turmeric extract.
Jan 3
2021
 Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
94% lower progression (p=0.001), 38% improved recovery (p=0.04), and 45% shorter hospitalization (p=0.001). Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
Nov 16
2020
 Dound et al., Journal of Clinical Trials, S3:004 A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19)
75% improved recovery (p=0.001) and 100% improved 7-point scale results (p=0.0001). RCT 200 COVID-19 positive patients in India, 100 treated with curcumin, vitamin C, vitamin K2-7, and selenomethionine, showing faster recovery with treatment.
Nov 13
2020
 Kritis et al., Metabolism Open, doi:10.1016/j.metop.2020.100066 The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19
Review of the potential benefits of bromelain and curcumin for COVID-19, and potential synergistic effects of the combination.
Oct 20
2020
 Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
50% lower mortality (p=0.3). Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR..
Oct 16
2020
 Rajagopal et al., Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach
In silico study of several phytochemical compounds from Curcuma longa (turmeric) and Andrographis paniculata for their potential activity against COVID-19 by targeting the SARS-CoV-2 main protease. Molecular docking analysis found the tur..
Jun 7
2020
 Suravajhala et al., Preprints, doi:10.20944/preprints202005.0439.v3 Comparative Docking Studies on Curcumin with COVID-19 Proteins
In silico study showing high binding affinity for the SARS-CoV-2 nucleocapsid and nsp10 proteins with curcumin. Authors propose curcumin for COVID-19 drug development.
Jun 4
2020
 Hooper, P., Cell Stress and Chaperones, doi:10.1007/s12192-020-01126-9 COVID-19 and heme oxygenase: novel insight into the disease and potential therapies
Proposal that COVID-19 risk is related to low intracellular heme oxygenase (HO-1), and that therapies that raise HO-1 may be beneficial, which includes fluvoxamine, certain anesthetics (sevoflurane or isoflurane), hemin, estrogen, statins..
Apr 24
2020
 Sekiou et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2
In silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2.